Empowered Patient Podcast

Dr. Dolca Thomas is the Executive VP of Research and Development and Chief Medical Officer at Equillium, targeting autoimmune diseases where patients do not have a medicine that can lead to complete remission. In development, is the drug itolizumab considered a first-in-class, that focuses on the specific target and impacts what is known in the immune response as costimulation.

Dolca elaborates, "Right now, at Equillium, we're focusing on three difficult to treat autoimmune diseases. The first is graft-versus-host disease. This is a condition that develops in patients after they've had a bone marrow transplant where the donor cells that are used to treat the malignancy, the cancer that the patient has, then, later on, starts to attack the cells that belong to the patient. This is a disease that can occur anytime from immediately after transplant up to 100 days post-transplant"

"The second area where we're focused on is related to autoimmune disorders and diseases is lupus nephritis. Lupus nephritis is a disease that typically impacts women, young women, and women of color."

"The third area of focus for us as it relates to difficult to treat autoimmune diseases is asthma. There's still a need for other new therapies to help the 60% of patients that aren't positively impacted as it relates to their asthmatic control."

@EquilliumBio #Equillium #AutoimmuneDiseases #AutoimmuneDisorders #Nephritis #aGVHD #GraftversusHostDisease #Itolizumab #LupusNephritis #CD6ALCAM #RareDisease #SanDiego

equilliumbio.com

Listen to the podcast here

Dr. Dolca Thomas is the Executive VP of Research and Development and Chief Medical Officer at Equillium, targeting autoimmune diseases where patients do not have a medicine that can lead to complete remission. In development, is the drug itolizumab considered a first-in-class, that focuses on the specific target and impacts what is known in the immune response as costimulation.

Dolca elaborates, "Right now, at Equillium, we're focusing on three difficult to treat autoimmune diseases. The first is graft-versus-host disease. This is a condition that develops in patients after they've had a bone marrow transplant where the donor cells that are used to treat the malignancy, the cancer that the patient has, then, later on, starts to attack the cells that belong to the patient. This is a disease that can occur anytime from immediately after transplant up to 100 days post-transplant"

"The second area where we're focused on is related to autoimmune disorders and diseases is lupus nephritis. Lupus nephritis is a disease that typically impacts women, young women, and women of color."

"The third area of focus for us as it relates to difficult to treat autoimmune diseases is asthma. There's still a need for other new therapies to help the 60% of patients that aren't positively impacted as it relates to their asthmatic control."

@EquilliumBio #Equillium #AutoimmuneDiseases #AutoimmuneDisorders #Nephritis #aGVHD #GraftversusHostDisease #Itolizumab #LupusNephritis #CD6ALCAM #RareDisease #SanDiego

equilliumbio.com

Download the transcript here

Tom Lemberg is the Founder and CEO of Curebase and was recently included in the Forbes 30 under 30 list for 2022 for leading positive global change in healthcare. Curebase is shaking up the world of clinical trials by providing software for patients making it easy for them to participate from home, software for doctors that makes it easy for them to participate in the research, along with a virtual research site model that has grown even more valuable due to the pandemic.

Tom explains, "In terms of what Curebase does, we're a full platform for what's called a decentralized clinical trial. So, that means taking trials out of the elite institutions and bringing them to patients at home. We have an app for patients which guides them through things like discovering trials, submitting data at home, connecting medical records, scheduling telemedicine appointments, conducting telemedicine appointments, and participating in treatments from home."

"We also have software for physicians. So we've brought over 100 community physicians, so sort of first-time researchers, into the clinical trial world using our software to make it easy for them to participate."

"Through the software and our virtual site model, we've really reduced the barriers to participation for patients and doctors, and that's what gets us into the idea of Bring Your Own Physician. So, Bring Your Own Physician is something that we're really pioneering. It's the idea that a patient could discover a clinical trial on the internet, sign up at home using our app or any other technology, and they could then participate with their own doctor."

@CurebaseDCT #DCT #DecentralizedDigitalTrials #ClinicalResearch #ClinicalTrials #BYOP #DigitalTherapeutics #DigitalHealth #Telemedicine

Curebase.com

Listen to the podcast here

Tom Lemberg is the Founder and CEO of Curebase and was recently included in the Forbes 30 under 30 list for 2022 for leading positive global change in healthcare. Curebase is shaking up the world of clinical trials by providing software for patients making it easy for them to participate from home, software for doctors that makes it easy for them to participate in the research, along with a virtual research site model that has grown even more valuable due to the pandemic.

Tom explains, "In terms of what Curebase does, we're a full platform for what's called a decentralized clinical trial. So, that means taking trials out of the elite institutions and bringing them to patients at home. We have an app for patients which guides them through things like discovering trials, submitting data at home, connecting medical records, scheduling telemedicine appointments, conducting telemedicine appointments, and participating in treatments from home."

"We also have software for physicians. So we've brought over 100 community physicians, so sort of first-time researchers, into the clinical trial world using our software to make it easy for them to participate."

"Through the software and our virtual site model, we've really reduced the barriers to participation for patients and doctors, and that's what gets us into the idea of Bring Your Own Physician. So, Bring Your Own Physician is something that we're really pioneering. It's the idea that a patient could discover a clinical trial on the internet, sign up at home using our app or any other technology, and they could then participate with their own doctor."

@CurebaseDCT #DCT #DecentralizedDigitalTrials #ClinicalResearch #ClinicalTrials #BYOP #DigitalTherapeutics #DigitalHealth #Telemedicine

Curebase.com

Download the transcript here

Dr. Joseph O'Donnell is the Chief Medical Officer at Phosplatin Therapeutics founded to develop a drug with platinum in it to kill cancer cells. Phosplatin is in clinical trials with PT-112 which is the first cancer therapy molecule that has a pyrophosphate on it and works by harnessing the immune system and causing immunogenic cell death.

Dr. Joe explains, "This drug is in this space that's really burgeoning called immuno-oncology, where we're using immune agents to stimulate the immune system to actually affect the cancer, to actually knock down the cancer. And this is one that has a different mechanism than some of the other agents and lots of potential to be used in combination to produce synergy with those other agents in this very exciting space."

"So, the checkpoint inhibitors are one group of drugs that seems to be interesting to combine with PT-112, and I suspect we'll see more of that in the future. But just PT-112 by itself, it has this effect called producing immunogenic cell death. That's a way in which a drug causes cancer cells to die by activating the immune system, the adaptive immune system, to actually attack the tumor and actually devour it. And so that's one of the properties that the PT-112 has."

@Phosplatin #Oncology #ImmunoOncology #Cancer #CancerTherapeutics #ICD #ImmunogenicCellDeath #Chemotherapy #CheckPointInhibitors #Innovation #NYBiotech

Phosplatin.com

Listen to the podcast here

Dr. Joseph O'Donnell is the Chief Medical Officer at Phosplatin Therapeutics founded to develop a drug with platinum in it to kill cancer cells. Phosplatin is in clinical trials with PT-112 which is the first cancer therapy molecule that has a pyrophosphate on it and works by harnessing the immune system and causing immunogenic cell death.

Dr. Joe explains, "This drug is in this space that's really burgeoning called immuno-oncology, where we're using immune agents to stimulate the immune system to actually affect the cancer, to actually knock down the cancer. And this is one that has a different mechanism than some of the other agents and lots of potential to be used in combination to produce synergy with those other agents in this very exciting space."

"So, the checkpoint inhibitors are one group of drugs that seems to be interesting to combine with PT-112, and I suspect we'll see more of that in the future. But just PT-112 by itself, it has this effect called producing immunogenic cell death. That's a way in which a drug causes cancer cells to die by activating the immune system, the adaptive immune system, to actually attack the tumor and actually devour it. And so that's one of the properties that the PT-112 has."

@Phosplatin #Oncology #ImmunoOncology #Cancer #CancerTherapeutics #ICD #ImmunogenicCellDeath #Chemotherapy #CheckPointInhibitors #Innovation #NYBiotech

Phosplatin.com

Download the transcript here

Alain Moussy is the Co-Founder and CEO of AB Science a clinical-stage company designing and developing novel drugs to address diseases with high unmet medical needs. Masitinib, their drug in development is being investigated in neurological diseases such as amyotrophic lateral sclerosis, Alzheimer's, and multiple sclerosis as well for severe forms of COVID-19 and as an antiviral anti-protease in ambulatory COVID-19 patients.

Alain explains, "We have started two such studies in amyotrophic lateral sclerosis (ALS) disease, which is well known across the world, and another one in a rare disease called Mastocytosis, and those two studies are up and running. We have also started a phase 2 in COVID with masitinib after the University of Chicago discovered that masitinib is actually a potent antiviral against the virus, which was actually a surprise for us. Now that we have this data, we are developing masitinib for COVID as an antiviral. And you know, Karen, we need an antiviral along with the vaccine to fight this pandemic."

"The development of masitinib in Covid was not anticipated because our drug was not designed to be an antiviral. It's just that the structure of the protease of the virus has a strong affinity with the structure of our compound by chance. The co-crystallizations of the protease of the virus with masitinib, which has been done by the University of Chicago, show that they match."

#ABScience #COVID19 #Masitinib #AntiviralDrug #ALS #Alzheimers #MS

AB-Science.com

Listen to the podcast here

Alain Moussy is the Co-Founder and CEO of AB Science a clinical-stage company designing and developing novel drugs to address diseases with high unmet medical needs. Masitinib, their drug in development is being investigated in neurological diseases such as amyotrophic lateral sclerosis, Alzheimer's, and multiple sclerosis as well for severe forms of COVID-19 and as an antiviral anti-protease in ambulatory COVID-19 patients.

Alain explains, "We have started two such studies in amyotrophic lateral sclerosis (ALS) disease, which is well known across the world, and another one in a rare disease called Mastocytosis, and those two studies are up and running. We have also started a phase 2 in COVID with masitinib after the University of Chicago discovered that masitinib is actually a potent antiviral against the virus, which was actually a surprise for us. Now that we have this data, we are developing masitinib for COVID as an antiviral. And you know, Karen, we need an antiviral along with the vaccine to fight this pandemic."

"The development of masitinib in Covid was not anticipated because our drug was not designed to be an antiviral. It's just that the structure of the protease of the virus has a strong affinity with the structure of our compound by chance. The co-crystallizations of the protease of the virus with masitinib, which has been done by the University of Chicago, show that they match."

#ABScience #COVID19 #Masitinib #AntiviralDrug #ALS #Alzheimers #MS

AB-Science.com

Download the transcript here

Dr. Abigail Hirsch is the Co-Founder of Lin Health which is bringing innovative chronic pain treatments to a broader audience thanks to their digital behavioral health platform. Lin Health members get specifically designed pain management plans and virtual access for support from a deep team of medical experts.

Abigail explains, "Then, let's get to the treatments that work for chronic pain. There's a seminal study that came out in JAMA this past fall, looking at a treatment called PRT, pain reprocessing therapy. There are some other papers with similar findings for similar therapies, but these are behavioral health techniques that were designed specifically to help turn down the pain processing system."

"There are very specific techniques that may look a little bit like some other things in behavioral health, a little bit like a cognitive-behavioral approach, a little bit like a mindfulness approach. Still, they actually are quite different because they were designed specifically to help the pain processing pathways learn to settle down the degree to which they're signaling pain, and they're incredibly effective."

#LinHealth #ChronicPain #PainProcessing #DigitalHealth #Telehealth #Telemedicine

Lin.Health

Listen to the podcast here

Dr. Abigail Hirsch is the Co-Founder of Lin Health which is bringing innovative chronic pain treatments to a broader audience thanks to their digital behavioral health platform. Lin Health members get specifically designed pain management plans and virtual access for support from a deep team of medical experts.

Abigail explains, "Then, let's get to the treatments that work for chronic pain. There's a seminal study that came out in JAMA this past fall, looking at a treatment called PRT, pain reprocessing therapy. There are some other papers with similar findings for similar therapies, but these are behavioral health techniques that were designed specifically to help turn down the pain processing system."

"There are very specific techniques that may look a little bit like some other things in behavioral health, a little bit like a cognitive-behavioral approach, a little bit like a mindfulness approach. Still, they actually are quite different because they were designed specifically to help the pain processing pathways learn to settle down the degree to which they're signaling pain, and they're incredibly effective."

#LinHealth #ChronicPain #PainProcessing #DigitalHealth #Telehealth #Telemedicine

Lin.Health

Download the transcript here